[Bendamustine for the treatment of follicular lymphoma]

Paquin M-C, Boulanger J
Record ID 32015001242
Authors' recomendations: According to studies, the first-line treatment of indolent follicular lymphoma with the BR combination is non-inferior or superior to the standard treatments R-CVP and R-CHOP in terms of progression-free survival. In patients who have recurrent disease, who have never received treatment that includes rituximab or who have achieved remission of at least 6 months duration following such treatment, the BR combination appears to be superior to FR and to bendamustine monotherapy. However, there are no data for evaluating the efficacy of this treatment in patients who have received BR as first-line therapy. Lastly, in patients with rituximab-refractory disease, bendamustine monotherapy is an effective treatment option.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Humans
  • Lymphoma, Follicular
  • Nitrogen Mustard Compounds
  • Antibodies, Monoclonal, Murine-Derived
  • Lymphoma, Non-Hodgkin
  • Treatment Outcome
Organisation Name: Institut national d'excellence en sante et en services sociaux
Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name: demande@inesss.qc.ca
Contact Email: demande@inesss.qc.ca
Copyright: ©Gouvernement du Québec/Institut national d'excellence en santé et en services sociaux
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.